| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 39 | 2023 | 503 | 4.410 |
Why?
|
| Pancreatectomy | 40 | 2023 | 804 | 3.630 |
Why?
|
| Pancreatic Fistula | 25 | 2022 | 146 | 3.310 |
Why?
|
| Pancreatic Neoplasms | 52 | 2022 | 5256 | 2.550 |
Why?
|
| Adenocarcinoma | 24 | 2021 | 6364 | 1.160 |
Why?
|
| Kupffer Cells | 13 | 2000 | 142 | 1.090 |
Why?
|
| Pancreatic Diseases | 9 | 2020 | 350 | 1.010 |
Why?
|
| Cholecystectomy, Laparoscopic | 12 | 2017 | 230 | 0.960 |
Why?
|
| Laparoscopy | 25 | 2015 | 2151 | 0.960 |
Why?
|
| Pancreatitis, Chronic | 4 | 2015 | 285 | 0.810 |
Why?
|
| Postoperative Complications | 38 | 2023 | 15295 | 0.750 |
Why?
|
| Bile Ducts | 5 | 2017 | 284 | 0.610 |
Why?
|
| NF-kappa B | 8 | 2006 | 2499 | 0.550 |
Why?
|
| Deoxycytidine | 3 | 2011 | 826 | 0.540 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2005 | 4420 | 0.540 |
Why?
|
| Apoptosis | 10 | 2006 | 9727 | 0.530 |
Why?
|
| Gallbladder Neoplasms | 2 | 2017 | 183 | 0.520 |
Why?
|
| Blood Loss, Surgical | 7 | 2021 | 662 | 0.510 |
Why?
|
| Triage | 2 | 2021 | 976 | 0.480 |
Why?
|
| Lipopolysaccharides | 10 | 2001 | 2216 | 0.460 |
Why?
|
| Pancreas | 7 | 2020 | 1686 | 0.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 1634 | 0.460 |
Why?
|
| Multienzyme Complexes | 3 | 2002 | 686 | 0.450 |
Why?
|
| Decision Support Techniques | 6 | 2018 | 1956 | 0.450 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 990 | 0.440 |
Why?
|
| Boronic Acids | 4 | 2006 | 965 | 0.440 |
Why?
|
| I-kappa B Proteins | 4 | 2004 | 225 | 0.430 |
Why?
|
| Quality Indicators, Health Care | 6 | 2016 | 1831 | 0.420 |
Why?
|
| Bile Duct Diseases | 3 | 2015 | 100 | 0.410 |
Why?
|
| Dinoprostone | 7 | 1999 | 600 | 0.390 |
Why?
|
| Pyrazines | 4 | 2006 | 1230 | 0.390 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2001 | 437 | 0.390 |
Why?
|
| Thioredoxins | 1 | 2012 | 213 | 0.390 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2010 | 178 | 0.370 |
Why?
|
| Pancreatic Cyst | 5 | 2017 | 368 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 2212 | 0.360 |
Why?
|
| Sodium Salicylate | 2 | 1999 | 19 | 0.350 |
Why?
|
| Intraoperative Care | 2 | 2013 | 767 | 0.350 |
Why?
|
| Cysteine Endopeptidases | 3 | 2002 | 563 | 0.350 |
Why?
|
| Gallstones | 5 | 2022 | 286 | 0.340 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 358 | 0.340 |
Why?
|
| Hospital Costs | 6 | 2018 | 985 | 0.330 |
Why?
|
| Endotoxins | 3 | 1999 | 527 | 0.330 |
Why?
|
| Radiosurgery | 3 | 2017 | 1329 | 0.320 |
Why?
|
| Cough | 2 | 2002 | 555 | 0.320 |
Why?
|
| Portacaval Shunt, Surgical | 5 | 1990 | 49 | 0.320 |
Why?
|
| Drainage | 8 | 2021 | 1142 | 0.320 |
Why?
|
| Portal Vein | 9 | 2001 | 437 | 0.310 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2017 | 3479 | 0.310 |
Why?
|
| Risk Assessment | 27 | 2021 | 23338 | 0.310 |
Why?
|
| Cholangiography | 4 | 2013 | 189 | 0.300 |
Why?
|
| Pancreaticojejunostomy | 3 | 2013 | 26 | 0.300 |
Why?
|
| Gastroesophageal Reflux | 4 | 2002 | 782 | 0.300 |
Why?
|
| Pneumoperitoneum, Artificial | 6 | 2001 | 40 | 0.300 |
Why?
|
| Fundoplication | 3 | 2002 | 138 | 0.290 |
Why?
|
| Propensity Score | 8 | 2021 | 1781 | 0.290 |
Why?
|
| Cholestasis | 3 | 2019 | 378 | 0.290 |
Why?
|
| Endoscopy | 4 | 2021 | 1785 | 0.290 |
Why?
|
| Ubiquitin | 2 | 2002 | 852 | 0.280 |
Why?
|
| Liver Transplantation | 9 | 2006 | 2119 | 0.280 |
Why?
|
| Cell Nucleus | 3 | 2012 | 2969 | 0.280 |
Why?
|
| Hydroxamic Acids | 2 | 2006 | 494 | 0.280 |
Why?
|
| Humans | 151 | 2023 | 744343 | 0.280 |
Why?
|
| Patient Discharge | 4 | 2023 | 3313 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 2728 | 0.260 |
Why?
|
| Duodenal Neoplasms | 2 | 2014 | 106 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 640 | 0.260 |
Why?
|
| Risk Factors | 43 | 2023 | 72290 | 0.260 |
Why?
|
| Caspases | 2 | 2006 | 928 | 0.250 |
Why?
|
| Bile Duct Neoplasms | 2 | 2010 | 567 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2001 | 2938 | 0.250 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2006 | 295 | 0.250 |
Why?
|
| Retrospective Studies | 49 | 2023 | 77449 | 0.250 |
Why?
|
| Macrophages | 6 | 2001 | 5655 | 0.250 |
Why?
|
| Octreotide | 4 | 2018 | 145 | 0.240 |
Why?
|
| Critical Pathways | 2 | 2011 | 476 | 0.240 |
Why?
|
| Aged | 67 | 2023 | 163280 | 0.240 |
Why?
|
| Cholecystectomy | 4 | 2017 | 395 | 0.240 |
Why?
|
| Education, Medical, Continuing | 3 | 2021 | 840 | 0.240 |
Why?
|
| Hepatitis | 1 | 2005 | 227 | 0.230 |
Why?
|
| Treatment Outcome | 41 | 2019 | 63114 | 0.230 |
Why?
|
| Stents | 5 | 2018 | 3280 | 0.230 |
Why?
|
| Male | 99 | 2023 | 350118 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 8 | 2004 | 6314 | 0.220 |
Why?
|
| Fishes | 1 | 2006 | 569 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2001 | 1285 | 0.220 |
Why?
|
| Meat | 1 | 2006 | 592 | 0.220 |
Why?
|
| Middle Aged | 74 | 2023 | 213383 | 0.220 |
Why?
|
| Liver Neoplasms | 5 | 2005 | 4253 | 0.220 |
Why?
|
| Postoperative Care | 2 | 2013 | 1486 | 0.220 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2002 | 1338 | 0.220 |
Why?
|
| Length of Stay | 15 | 2021 | 6309 | 0.210 |
Why?
|
| Female | 97 | 2023 | 380194 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2005 | 1097 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Emergencies | 2 | 2014 | 1170 | 0.200 |
Why?
|
| Interleukin-6 | 6 | 2000 | 3200 | 0.200 |
Why?
|
| Immunophilins | 1 | 2001 | 20 | 0.200 |
Why?
|
| Macrophage Activation | 3 | 2000 | 558 | 0.200 |
Why?
|
| Liver Regeneration | 3 | 1993 | 210 | 0.200 |
Why?
|
| Neoplasm Staging | 9 | 2017 | 11031 | 0.200 |
Why?
|
| Peptide Hydrolases | 2 | 2002 | 634 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 789 | 0.190 |
Why?
|
| Liver | 19 | 2002 | 7474 | 0.190 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2001 | 205 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 516 | 0.190 |
Why?
|
| Carcinoma | 1 | 2012 | 2375 | 0.190 |
Why?
|
| Patient Selection | 6 | 2020 | 4215 | 0.190 |
Why?
|
| Pain, Postoperative | 3 | 2019 | 1643 | 0.180 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 1990 | 745 | 0.180 |
Why?
|
| Immune Tolerance | 6 | 1991 | 2258 | 0.180 |
Why?
|
| Fatty Liver | 1 | 2005 | 727 | 0.170 |
Why?
|
| Time Factors | 25 | 2018 | 40075 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 1198 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 2282 | 0.170 |
Why?
|
| Immunity, Cellular | 2 | 2004 | 1607 | 0.170 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2016 | 47 | 0.170 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 190 | 0.170 |
Why?
|
| Survival Rate | 9 | 2019 | 12788 | 0.170 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1999 | 114 | 0.170 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12245 | 0.170 |
Why?
|
| Cecal Neoplasms | 1 | 2018 | 29 | 0.160 |
Why?
|
| Cyclins | 1 | 2001 | 603 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3843 | 0.160 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2012 | 198 | 0.160 |
Why?
|
| Abdominal Muscles | 1 | 2019 | 166 | 0.160 |
Why?
|
| Granular Cell Tumor | 1 | 2018 | 51 | 0.160 |
Why?
|
| General Surgery | 2 | 2007 | 1636 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 896 | 0.160 |
Why?
|
| Aged, 80 and over | 28 | 2022 | 57776 | 0.160 |
Why?
|
| Arginine | 3 | 1993 | 944 | 0.160 |
Why?
|
| Pancreatic Pseudocyst | 2 | 2009 | 110 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1434 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1996 | 1130 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 1 | 2000 | 345 | 0.160 |
Why?
|
| Liver Circulation | 6 | 2002 | 164 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 494 | 0.150 |
Why?
|
| Cecum | 1 | 2018 | 237 | 0.150 |
Why?
|
| Rats, Inbred WF | 10 | 1991 | 140 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2001 | 5021 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 6 | 2010 | 504 | 0.150 |
Why?
|
| Ubiquitins | 1 | 1999 | 384 | 0.150 |
Why?
|
| Patient Readmission | 7 | 2023 | 3114 | 0.150 |
Why?
|
| Pressure Ulcer | 1 | 2018 | 155 | 0.150 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13695 | 0.150 |
Why?
|
| Preoperative Care | 5 | 2009 | 2250 | 0.150 |
Why?
|
| Rehabilitation Centers | 1 | 2018 | 254 | 0.150 |
Why?
|
| Ischemic Preconditioning | 3 | 2002 | 92 | 0.150 |
Why?
|
| Ampulla of Vater | 2 | 2007 | 141 | 0.140 |
Why?
|
| Ganglioneuroma | 1 | 1996 | 57 | 0.140 |
Why?
|
| Rats | 23 | 2001 | 24260 | 0.140 |
Why?
|
| Severity of Illness Index | 13 | 2016 | 15540 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2003 | 1951 | 0.140 |
Why?
|
| Protease Inhibitors | 3 | 2006 | 791 | 0.140 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 1540 | 0.130 |
Why?
|
| Constriction, Pathologic | 3 | 2015 | 1107 | 0.130 |
Why?
|
| Isoantigens | 4 | 1991 | 567 | 0.130 |
Why?
|
| Cell Division | 5 | 2001 | 4568 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 814 | 0.130 |
Why?
|
| Enzyme Inhibitors | 5 | 2006 | 3798 | 0.130 |
Why?
|
| Common Bile Duct | 1 | 1995 | 109 | 0.130 |
Why?
|
| Quality of Life | 1 | 2017 | 12804 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2014 | 643 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.130 |
Why?
|
| Celiac Artery | 1 | 2015 | 69 | 0.130 |
Why?
|
| Islets of Langerhans | 6 | 2010 | 1352 | 0.130 |
Why?
|
| Graft Survival | 10 | 2006 | 3737 | 0.120 |
Why?
|
| Type C Phospholipases | 1 | 1995 | 292 | 0.120 |
Why?
|
| Carbon Dioxide | 3 | 2001 | 1150 | 0.120 |
Why?
|
| Androstadienes | 1 | 1996 | 346 | 0.120 |
Why?
|
| Boston | 8 | 2018 | 9313 | 0.120 |
Why?
|
| Hypersensitivity, Delayed | 3 | 1990 | 484 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 931 | 0.120 |
Why?
|
| Macrophages, Peritoneal | 1 | 1995 | 251 | 0.120 |
Why?
|
| bcl-X Protein | 2 | 2006 | 411 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2003 | 2107 | 0.120 |
Why?
|
| CA-19-9 Antigen | 2 | 2011 | 111 | 0.120 |
Why?
|
| Morbidity | 5 | 2019 | 1769 | 0.120 |
Why?
|
| Prognosis | 8 | 2021 | 29063 | 0.120 |
Why?
|
| Infection Control | 1 | 2021 | 966 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5137 | 0.120 |
Why?
|
| Duodenal Diseases | 1 | 1994 | 102 | 0.110 |
Why?
|
| Pancreatitis | 3 | 2009 | 1092 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2016 | 2348 | 0.110 |
Why?
|
| Paraganglioma | 1 | 2014 | 143 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 1770 | 0.110 |
Why?
|
| Portal System | 2 | 1990 | 52 | 0.110 |
Why?
|
| Diverticulum | 1 | 1994 | 136 | 0.110 |
Why?
|
| Biliary Tract Diseases | 2 | 2013 | 161 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 413 | 0.110 |
Why?
|
| Hamartoma | 1 | 2014 | 238 | 0.110 |
Why?
|
| Adult | 38 | 2021 | 214055 | 0.110 |
Why?
|
| Reoperation | 5 | 2017 | 4201 | 0.110 |
Why?
|
| Signal Transduction | 5 | 2002 | 23403 | 0.110 |
Why?
|
| Nerve Block | 1 | 2019 | 644 | 0.110 |
Why?
|
| Lipoma | 1 | 2014 | 334 | 0.100 |
Why?
|
| Florida | 3 | 2020 | 435 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2020 | 3749 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2001 | 2440 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2001 | 8436 | 0.100 |
Why?
|
| Language | 1 | 2021 | 1471 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2000 | 3870 | 0.100 |
Why?
|
| Immunity | 1 | 1998 | 1012 | 0.100 |
Why?
|
| Cost Savings | 2 | 2007 | 926 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2006 | 1792 | 0.100 |
Why?
|
| Logistic Models | 7 | 2016 | 13408 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2004 | 3701 | 0.100 |
Why?
|
| Indomethacin | 5 | 1993 | 332 | 0.100 |
Why?
|
| Animals | 44 | 2006 | 168757 | 0.100 |
Why?
|
| Clinical Competence | 5 | 2020 | 4687 | 0.100 |
Why?
|
| ROC Curve | 3 | 2015 | 3527 | 0.100 |
Why?
|
| United States | 17 | 2019 | 69872 | 0.100 |
Why?
|
| Anastomosis, Surgical | 3 | 2021 | 987 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1372 | 0.100 |
Why?
|
| Odds Ratio | 5 | 2016 | 9849 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 4933 | 0.100 |
Why?
|
| Drug Tolerance | 3 | 1999 | 376 | 0.100 |
Why?
|
| Mitogens | 2 | 2001 | 232 | 0.100 |
Why?
|
| Hypoglycemia | 2 | 2010 | 861 | 0.100 |
Why?
|
| Colorectal Neoplasms | 3 | 2006 | 6773 | 0.090 |
Why?
|
| Peritoneum | 2 | 2004 | 228 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2020 | 3743 | 0.090 |
Why?
|
| Receptors, Glucagon | 1 | 2010 | 92 | 0.090 |
Why?
|
| Perioperative Care | 3 | 2012 | 1002 | 0.090 |
Why?
|
| Ultrasonography | 4 | 2012 | 5985 | 0.090 |
Why?
|
| Databases, Factual | 7 | 2019 | 7729 | 0.090 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 8642 | 0.090 |
Why?
|
| Hepatectomy | 5 | 2001 | 550 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 576 | 0.090 |
Why?
|
| Nomograms | 1 | 2011 | 228 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2019 | 3508 | 0.090 |
Why?
|
| Gastric Bypass | 2 | 2010 | 812 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2015 | 10252 | 0.090 |
Why?
|
| Efficiency | 1 | 2012 | 462 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3610 | 0.090 |
Why?
|
| S Phase | 2 | 2001 | 423 | 0.090 |
Why?
|
| Incidental Findings | 2 | 2017 | 689 | 0.080 |
Why?
|
| Amylases | 1 | 2009 | 173 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 215 | 0.080 |
Why?
|
| G1 Phase | 2 | 2001 | 415 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2000 | 5179 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2014 | 730 | 0.080 |
Why?
|
| Spleen | 6 | 1993 | 2362 | 0.080 |
Why?
|
| Cause of Death | 2 | 2017 | 3584 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2005 | 11524 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 2959 | 0.080 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 15076 | 0.080 |
Why?
|
| Mucins | 1 | 2012 | 564 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2015 | 1063 | 0.080 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 494 | 0.080 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 328 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2002 | 2967 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 594 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 126 | 0.080 |
Why?
|
| Models, Economic | 2 | 2016 | 713 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 280 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2012 | 20129 | 0.080 |
Why?
|
| Gallbladder Diseases | 1 | 2009 | 125 | 0.080 |
Why?
|
| Phagocytosis | 3 | 1990 | 1539 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 1991 | 675 | 0.080 |
Why?
|
| Palliative Care | 2 | 2019 | 3493 | 0.080 |
Why?
|
| Delirium | 1 | 2019 | 1609 | 0.080 |
Why?
|
| Aspirin | 1 | 2000 | 3282 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6538 | 0.080 |
Why?
|
| Diet | 1 | 2006 | 7939 | 0.080 |
Why?
|
| Duodenal Ulcer | 1 | 2007 | 125 | 0.080 |
Why?
|
| Flavonoids | 2 | 2001 | 443 | 0.080 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 39050 | 0.080 |
Why?
|
| Prospective Studies | 10 | 2023 | 53288 | 0.080 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 415 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2007 | 14722 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2001 | 697 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2002 | 1227 | 0.070 |
Why?
|
| Cryopreservation | 2 | 2002 | 670 | 0.070 |
Why?
|
| Cell Line | 5 | 2004 | 15997 | 0.070 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2007 | 111 | 0.070 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 1681 | 0.070 |
Why?
|
| Models, Biological | 4 | 2012 | 9583 | 0.070 |
Why?
|
| Incidence | 6 | 2021 | 20947 | 0.070 |
Why?
|
| Kinetics | 5 | 1996 | 6473 | 0.070 |
Why?
|
| Linear Models | 2 | 2013 | 5952 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4371 | 0.060 |
Why?
|
| Quinones | 1 | 2005 | 76 | 0.060 |
Why?
|
| Cell Separation | 3 | 2000 | 1751 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 3674 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2453 | 0.060 |
Why?
|
| Angiography | 2 | 2007 | 1639 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2007 | 571 | 0.060 |
Why?
|
| Cholecystitis | 1 | 2005 | 182 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 3396 | 0.060 |
Why?
|
| Analgesia, Epidural | 1 | 2008 | 327 | 0.060 |
Why?
|
| Blood Vessels | 2 | 2010 | 1125 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2004 | 77 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2015 | 3209 | 0.060 |
Why?
|
| User-Computer Interface | 3 | 2007 | 1431 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 2879 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 484 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2004 | 71 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 440 | 0.060 |
Why?
|
| Cells, Cultured | 7 | 2001 | 19229 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2005 | 201 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2015 | 2616 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2006 | 16689 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 1018 | 0.060 |
Why?
|
| Swine | 10 | 2002 | 5917 | 0.060 |
Why?
|
| Massachusetts | 4 | 2021 | 8663 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2000 | 8301 | 0.060 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 197 | 0.060 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2004 | 107 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1275 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2174 | 0.060 |
Why?
|
| Sirolimus | 2 | 2001 | 1564 | 0.060 |
Why?
|
| Age Factors | 5 | 2017 | 18370 | 0.060 |
Why?
|
| Hernia, Inguinal | 2 | 1996 | 210 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 17446 | 0.060 |
Why?
|
| Biopsy | 2 | 2009 | 6756 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3887 | 0.060 |
Why?
|
| Lactams, Macrocyclic | 1 | 2005 | 320 | 0.060 |
Why?
|
| Pain Measurement | 4 | 2019 | 3420 | 0.060 |
Why?
|
| Risk Adjustment | 2 | 2017 | 594 | 0.050 |
Why?
|
| Escherichia coli | 2 | 1996 | 4217 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 275 | 0.050 |
Why?
|
| Educational Measurement | 2 | 2009 | 1210 | 0.050 |
Why?
|
| Endosonography | 1 | 2006 | 610 | 0.050 |
Why?
|
| Gastric Acidity Determination | 1 | 2002 | 62 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2019 | 21746 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2002 | 2455 | 0.050 |
Why?
|
| Cohort Studies | 8 | 2021 | 40561 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 769 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 1624 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 758 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 1439 | 0.050 |
Why?
|
| Liver Diseases | 2 | 1995 | 1253 | 0.050 |
Why?
|
| Transplantation, Autologous | 4 | 1997 | 2124 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2005 | 434 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 1411 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 4851 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 1094 | 0.050 |
Why?
|
| Tuftsin | 1 | 1981 | 4 | 0.050 |
Why?
|
| Peptide Initiation Factors | 1 | 2001 | 56 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2004 | 1682 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 1990 | 1401 | 0.050 |
Why?
|
| Rats, Inbred Lew | 7 | 1991 | 1162 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2001 | 94 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2016 | 6459 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 1475 | 0.050 |
Why?
|
| Comorbidity | 3 | 2023 | 10388 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 1981 | 84 | 0.050 |
Why?
|
| Embolism, Air | 1 | 2001 | 111 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1991 | 2186 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2001 | 107 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 2001 | 220 | 0.050 |
Why?
|
| Chromones | 1 | 2000 | 154 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2003 | 389 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 365 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1758 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2009 | 5391 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2001 | 5974 | 0.040 |
Why?
|
| Learning Curve | 1 | 2021 | 208 | 0.040 |
Why?
|
| Mexico | 1 | 2022 | 690 | 0.040 |
Why?
|
| Environment | 1 | 2006 | 1124 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 480 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1213 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2009 | 9146 | 0.040 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 19905 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 1157 | 0.040 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2010 | 101 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 135 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2004 | 1539 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 489 | 0.040 |
Why?
|
| Probability | 2 | 2002 | 2505 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 8428 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1991 | 371 | 0.040 |
Why?
|
| Dipeptides | 1 | 2001 | 409 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1999 | 149 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 342 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 3158 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 242 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 9648 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2005 | 2234 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 1999 | 245 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2005 | 1538 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 778 | 0.040 |
Why?
|
| Laparotomy | 1 | 2000 | 473 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 1990 | 964 | 0.040 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 1026 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2021 | 398 | 0.040 |
Why?
|
| Biliary Tract | 2 | 1996 | 134 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2019 | 2886 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2000 | 463 | 0.040 |
Why?
|
| Camptothecin | 1 | 2001 | 576 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1993 | 1263 | 0.040 |
Why?
|
| Ibuprofen | 1 | 1999 | 236 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 1999 | 367 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 692 | 0.040 |
Why?
|
| Heart Transplantation | 4 | 1991 | 3110 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 2291 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1990 | 1827 | 0.040 |
Why?
|
| Morpholines | 1 | 2000 | 571 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2002 | 5172 | 0.040 |
Why?
|
| Hospital Mortality | 3 | 2016 | 5317 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 1990 | 1150 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 12354 | 0.040 |
Why?
|
| Cholecystography | 1 | 1996 | 42 | 0.040 |
Why?
|
| Kidney | 4 | 1997 | 7186 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2010 | 3616 | 0.030 |
Why?
|
| Gadolinium | 3 | 1990 | 952 | 0.030 |
Why?
|
| Nitrites | 1 | 1996 | 160 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2001 | 424 | 0.030 |
Why?
|
| Organoids | 1 | 2022 | 701 | 0.030 |
Why?
|
| Abdomen | 3 | 2007 | 1118 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1997 | 292 | 0.030 |
Why?
|
| Internationality | 1 | 2021 | 1003 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1996 | 379 | 0.030 |
Why?
|
| Tyrosine | 2 | 2001 | 1461 | 0.030 |
Why?
|
| Bupivacaine | 1 | 2019 | 411 | 0.030 |
Why?
|
| Selection Bias | 1 | 2017 | 371 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 1996 | 140 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2924 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3474 | 0.030 |
Why?
|
| Vascular Neoplasms | 1 | 1997 | 175 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 764 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2000 | 612 | 0.030 |
Why?
|
| Insulin | 2 | 2005 | 6580 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2005 | 6196 | 0.030 |
Why?
|
| Perfusion | 1 | 1999 | 1360 | 0.030 |
Why?
|
| Ischemia | 2 | 2001 | 1907 | 0.030 |
Why?
|
| Neoplasms | 2 | 2001 | 21683 | 0.030 |
Why?
|
| Imidazoles | 1 | 2001 | 1206 | 0.030 |
Why?
|
| Dogs | 2 | 1990 | 3912 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2002 | 528 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1995 | 520 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 610 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2015 | 80 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2001 | 3689 | 0.030 |
Why?
|
| Research | 1 | 2003 | 1999 | 0.030 |
Why?
|
| Cost of Illness | 2 | 2015 | 1859 | 0.030 |
Why?
|
| Phosphatidylinositols | 1 | 1995 | 291 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1998 | 1588 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2001 | 1640 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 1996 | 250 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3768 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2274 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 1997 | 382 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1990 | 1116 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 2126 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1997 | 440 | 0.030 |
Why?
|
| Hernia, Ventral | 1 | 1996 | 176 | 0.030 |
Why?
|
| Young Adult | 6 | 2017 | 56430 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2016 | 437 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 1993 | 185 | 0.030 |
Why?
|
| Appendectomy | 1 | 1996 | 401 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12959 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 3557 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6365 | 0.030 |
Why?
|
| Pain | 1 | 2008 | 4986 | 0.030 |
Why?
|
| Splenectomy | 1 | 2014 | 395 | 0.030 |
Why?
|
| Models, Anatomic | 2 | 2009 | 691 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1997 | 477 | 0.030 |
Why?
|
| Benzophenanthridines | 2 | 2002 | 27 | 0.030 |
Why?
|
| Mucin-2 | 1 | 2012 | 49 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 2503 | 0.030 |
Why?
|
| Phenanthridines | 2 | 2002 | 51 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1842 | 0.030 |
Why?
|
| Philadelphia | 1 | 2012 | 266 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2012 | 93 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2001 | 2109 | 0.030 |
Why?
|
| Models, Animal | 3 | 2003 | 2171 | 0.020 |
Why?
|
| Reference Values | 1 | 2019 | 4982 | 0.020 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 1991 | 22 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 1995 | 924 | 0.020 |
Why?
|
| Rats, Inbred BUF | 4 | 1991 | 19 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1991 | 252 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1991 | 517 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1991 | 919 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 806 | 0.020 |
Why?
|
| Alkaloids | 2 | 2002 | 190 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2018 | 1062 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 46 | 0.020 |
Why?
|
| Cell Survival | 2 | 1999 | 5882 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2915 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 1993 | 407 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2016 | 1147 | 0.020 |
Why?
|
| Menstruation | 1 | 1992 | 302 | 0.020 |
Why?
|
| Video Recording | 1 | 1995 | 949 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 1990 | 6386 | 0.020 |
Why?
|
| Transplantation, Homologous | 6 | 2002 | 4776 | 0.020 |
Why?
|
| Extracorporeal Circulation | 2 | 2002 | 182 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1990 | 1420 | 0.020 |
Why?
|
| Blood Volume | 1 | 2011 | 565 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 1990 | 175 | 0.020 |
Why?
|
| Insulinoma | 1 | 2010 | 124 | 0.020 |
Why?
|
| Bile | 2 | 2001 | 299 | 0.020 |
Why?
|
| Autoradiography | 1 | 2010 | 745 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15226 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2418 | 0.020 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1989 | 59 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 908 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 432 | 0.020 |
Why?
|
| Pyridines | 1 | 2001 | 2825 | 0.020 |
Why?
|
| Insurance, Liability | 1 | 2009 | 102 | 0.020 |
Why?
|
| Digestive System | 1 | 1990 | 253 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.020 |
Why?
|
| Fear | 1 | 2017 | 1440 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 1989 | 236 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 1996 | 1171 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 4554 | 0.020 |
Why?
|
| Endothelium | 2 | 2001 | 778 | 0.020 |
Why?
|
| Benchmarking | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2009 | 719 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 7722 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2009 | 211 | 0.020 |
Why?
|
| Colon | 1 | 1996 | 1772 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 1989 | 509 | 0.020 |
Why?
|
| Indocyanine Green | 1 | 1989 | 239 | 0.020 |
Why?
|
| Insurance Carriers | 1 | 2009 | 157 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1995 | 1486 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2012 | 543 | 0.020 |
Why?
|
| Mice | 5 | 2001 | 81183 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 2635 | 0.020 |
Why?
|
| Cold Temperature | 2 | 2001 | 772 | 0.020 |
Why?
|
| Tissue Donors | 2 | 2002 | 2240 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1989 | 719 | 0.020 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 110 | 0.020 |
Why?
|
| Critical Care | 2 | 2011 | 2647 | 0.020 |
Why?
|
| Choristoma | 1 | 1988 | 213 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1989 | 625 | 0.020 |
Why?
|
| Duodenum | 1 | 2010 | 483 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 683 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10943 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 7913 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2005 | 18 | 0.020 |
Why?
|
| Adolescent | 4 | 2016 | 85781 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2010 | 650 | 0.020 |
Why?
|
| Diazoxide | 1 | 2005 | 57 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12745 | 0.020 |
Why?
|
| Risk Management | 1 | 2009 | 571 | 0.020 |
Why?
|
| Mutation | 3 | 2000 | 29786 | 0.020 |
Why?
|
| Miniaturization | 1 | 2005 | 164 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1590 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 1301 | 0.020 |
Why?
|
| Caffeine | 1 | 1989 | 699 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1990 | 2008 | 0.020 |
Why?
|
| Diet Therapy | 1 | 2005 | 154 | 0.020 |
Why?
|
| Malpractice | 1 | 2009 | 572 | 0.020 |
Why?
|
| Body Weight | 3 | 1990 | 4669 | 0.010 |
Why?
|
| Esthetics | 1 | 2005 | 306 | 0.010 |
Why?
|
| Stomach | 1 | 1988 | 697 | 0.010 |
Why?
|
| Cholelithiasis | 2 | 1995 | 414 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 11366 | 0.010 |
Why?
|
| Medical Errors | 1 | 2011 | 1297 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2008 | 969 | 0.010 |
Why?
|
| Anxiety | 1 | 2017 | 4297 | 0.010 |
Why?
|
| Movement | 1 | 2010 | 1471 | 0.010 |
Why?
|
| Genistein | 1 | 2002 | 88 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 1185 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2708 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 719 | 0.010 |
Why?
|
| Intubation | 1 | 2002 | 141 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2014 | 2494 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 4251 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2007 | 1534 | 0.010 |
Why?
|
| Taurocholic Acid | 1 | 2001 | 43 | 0.010 |
Why?
|
| Cholagogues and Choleretics | 1 | 2001 | 32 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1990 | 21827 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2001 | 275 | 0.010 |
Why?
|
| Algorithms | 2 | 2015 | 13881 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1989 | 3913 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 868 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4217 | 0.010 |
Why?
|
| Analgesia | 1 | 2005 | 461 | 0.010 |
Why?
|
| Hemodynamics | 2 | 2002 | 4199 | 0.010 |
Why?
|
| Remote Consultation | 1 | 2003 | 238 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 1261 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1998 | 11483 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2000 | 5078 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1991 | 5524 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6566 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 2000 | 146 | 0.010 |
Why?
|
| Reperfusion | 1 | 2000 | 284 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 6895 | 0.010 |
Why?
|
| Cyclosporins | 2 | 1989 | 220 | 0.010 |
Why?
|
| Prodrugs | 1 | 2001 | 268 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2001 | 909 | 0.010 |
Why?
|
| Organ Preservation | 1 | 2001 | 331 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 592 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2001 | 369 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2001 | 936 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1999 | 411 | 0.010 |
Why?
|
| Pressure | 1 | 2001 | 1203 | 0.010 |
Why?
|
| Graft Rejection | 3 | 2002 | 4397 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 2531 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2000 | 395 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 1076 | 0.010 |
Why?
|
| Cysts | 2 | 1995 | 678 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2002 | 605 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 378 | 0.010 |
Why?
|
| Laparoscopes | 1 | 1996 | 41 | 0.010 |
Why?
|
| Curriculum | 1 | 2009 | 3605 | 0.010 |
Why?
|
| Medical Illustration | 1 | 1997 | 133 | 0.010 |
Why?
|
| Esophagus | 1 | 2002 | 1019 | 0.010 |
Why?
|
| Robotics | 1 | 2003 | 899 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2000 | 35421 | 0.010 |
Why?
|
| Phospholipids | 1 | 1999 | 784 | 0.010 |
Why?
|
| Phlebography | 1 | 1997 | 333 | 0.010 |
Why?
|
| Liver Abscess | 1 | 1996 | 82 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 3251 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1990 | 6256 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3582 | 0.010 |
Why?
|
| Ultraviolet Rays | 2 | 1990 | 1060 | 0.010 |
Why?
|
| Electrocoagulation | 1 | 1995 | 158 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 1901 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1981 | 1189 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1999 | 1100 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1981 | 3129 | 0.010 |
Why?
|
| Listeriosis | 1 | 1996 | 149 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13284 | 0.010 |
Why?
|
| Organ Size | 2 | 1990 | 2252 | 0.010 |
Why?
|
| Punctures | 1 | 1996 | 374 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1730 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 1869 | 0.010 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1994 | 41 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 1996 | 276 | 0.010 |
Why?
|
| Salicylic Acid | 1 | 1993 | 56 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1996 | 675 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13102 | 0.010 |
Why?
|
| Salicylates | 1 | 1993 | 126 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7181 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 1992 | 146 | 0.010 |
Why?
|
| Child | 2 | 1996 | 77709 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1996 | 2716 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 2917 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8340 | 0.010 |
Why?
|
| Microbial Collagenase | 1 | 1990 | 122 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1989 | 257 | 0.010 |
Why?
|
| Aorta | 1 | 1997 | 2061 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1981 | 13815 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1996 | 2751 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1989 | 471 | 0.000 |
Why?
|
| Intensive Care Units | 1 | 2000 | 3679 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1989 | 546 | 0.000 |
Why?
|
| Immunization | 1 | 1990 | 1256 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1991 | 1074 | 0.000 |
Why?
|
| Blood Pressure | 1 | 2001 | 8554 | 0.000 |
Why?
|
| Endometriosis | 1 | 1992 | 839 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1989 | 2242 | 0.000 |
Why?
|
| Internship and Residency | 1 | 2003 | 5788 | 0.000 |
Why?
|
| Acute Disease | 1 | 1994 | 7149 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18029 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1989 | 2617 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1997 | 9239 | 0.000 |
Why?
|
| Pregnancy | 1 | 1995 | 29144 | 0.000 |
Why?
|
| Infant | 1 | 1988 | 35136 | 0.000 |
Why?
|